Welcome to our dedicated page for Siemens A G news (Ticker: SIEGY), a resource for investors and traders seeking the latest updates and insights on Siemens A G stock.
Siemens AG (SIEGY) drives innovation across industrial automation, smart infrastructure, and healthcare technology. This dedicated news hub provides investors and professionals with direct access to official announcements and market-moving updates.
Track Siemens' latest developments through verified press releases and strategic communications. Our curated feed ensures you never miss critical information about operational milestones, technology partnerships, or sustainability initiatives.
All content undergoes strict verification to maintain accuracy and relevance. Explore updates spanning Siemens' core sectors including energy-efficient infrastructure solutions, factory automation advancements, and next-generation medical imaging systems.
Bookmark this page for streamlined access to SIEGY's evolving corporate narrative. Combine real-time alerts with historical context to better understand Siemens' role in shaping global industrial trends.
Siemens Healthineers has received FDA Emergency Use Authorization (EUA) for its CLINITEST Rapid COVID-19 Antigen Self-Test, allowing unsupervised self-testing for individuals aged 14 and over. The test provides results in just 15 minutes and is part of a nationwide retail distribution to meet increasing COVID-19 testing demands. The test has shown an accuracy with sensitivity at 86.5% and specificity at 99.3%, ensuring reliable results for users. The product is set to launch in January 2022, with production capabilities in the tens of millions per month.
Siemens Healthineers' ELF Test has been recognized as the top-performing biomarker in the NIMBLE study, as reported in a presentation at The Liver Meeting 2021. The ELF Test excelled in identifying fibrosis stages ≥2, with enhanced performance for stages ≥3 and 4. This recognition supports its potential to transform NASH clinical trials by reducing reliance on invasive liver biopsies. The NIMBLE project aims to validate non-invasive biomarkers for diagnosing NASH, impacting about 15 million people in the U.S. Successful regulatory qualification could revolutionize clinical trial methodologies.
Siemens Government Technologies has been awarded a contract over $1.78M by the FDA to implement an Advanced Digital Design and Manufacturing line as part of the FDA’s Advanced Manufacturing and Supply Chain programs. This partnership aims to enhance product development, increase manufacturing capacity, and improve product quality in the Lifesciences sector. The initiative will leverage Siemens Digital Industries’ software, facilitating the evaluation and adoption of advanced manufacturing processes, ultimately reducing supply chain shortages and accelerating responses to public health challenges.
Siemens Mobility's S700 streetcars began operating in Charlotte on August 21, 2021. These modern vehicles use innovative hybrid technology, allowing for both wired and wireless operation while maintaining sustainability. Manufactured in Sacramento, CA, the S700 fleet replaces outdated trolleys and expands the CityLYNX Gold Line by 2.5 miles. With features like enhanced safety systems and spacious design, these streetcars can carry up to 195 passengers and achieve speeds of 25 mph. The deployment marks a significant upgrade for urban transit, benefiting CATS and its riders.
Siemens Healthineers has received De Novo marketing authorization for the Enhanced Liver Fibrosis (ELF) Test, an innovative blood test for patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH). This test aids in assessing the risk of progression to cirrhosis and liver-related complications. The ELF Test, which was previously granted Breakthrough Device Designation in
Siemens is committing to expand its U.S. manufacturing operations to support electric vehicle (EV) infrastructure, planning to produce over 1 million EV chargers in the next four years. This investment aligns with the $1 trillion bipartisan infrastructure bill and aims to create 100 jobs. Siemens will unveil a new facility for AC charger manufacturing in early 2022, complementing its existing operations in North Carolina. The company emphasizes enhancing U.S. infrastructure and job growth in electrification.
Siemens and Dow are collaborating to demonstrate advanced automation technologies at MxD, a leading manufacturing institute in Chicago. This test bed showcases how innovative software, IoT, and digital tools can enhance efficiency and safety in process industries. Featuring Siemens’ SIMATIC PCS neo system, the test bed enables remote operation and real-time collaboration, empowering workers with augmented reality tools. With a focus on digital transformation, this initiative aims to improve productivity and create safer work environments, which is increasingly crucial in light of ongoing digitalization trends driven by the pandemic.
Siemens has launched the "Where the Jobs Are 2021" series at the SelectUSA Investment Summit, aiming to create awareness about job openings and training opportunities across the U.S. The initiative highlights over 2,000 available positions and emphasizes the importance of skilled workforce development, especially in the wake of the pandemic. Siemens invests $37 million annually in workforce training and plans to address the urgent demand for skilled trades jobs, which make up 32% of its hiring needs. The company collaborates with educational institutions to enhance training programs.
Siemens Advanta has partnered with Bleutech Park to develop a smart city project in Las Vegas, a $7.5 billion initiative expected to last over six years. This collaboration marks the beginning of the project’s first phase, focusing on creating a master plan for the campus infrastructure. The development aims to feature net-zero carbon footprint buildings and advanced technologies, including renewable energy sources and automated designs. Groundbreaking is anticipated in 2021, promising to create over 25,000 jobs and introduce a sustainable, interconnected community.
Siemens has unveiled its fully integrated modular production solution, leveraging SIMATIC PCS 7 and Sartorius’ SIMATIC Batch and Biostat STR DCU. The solution, showcased at the Sartorius Application Center in New York, allows for flexibility and speed in biopharmaceutical production, enabling quick adjustments to production lines. An agreement with Sartorius streamlines integration between their operations and Siemens’ control systems. This innovation supports both greenfield and brownfield installations, facilitating cGMP compliance and promoting a paperless manufacturing environment.
